



## 2012 European Medicines Agency/IFAH-Europe Info Day

'THE LATEST DEVELOPMENTS'
IN SCIENTIFIC REVIEW, LEGISLATION AND MARKETING AUTHORISATION PROCEDURES
8-9 March 2012, European Medicines Agency, London

## **Programme**

Thursday 8th March 2012			
13:30	Registration open		
14:00	Introduction and Welcome	Andreas Pott, EMA	
Session I: Scientific Developments		Chair: Rick Clayton, IFAH-Europe	
14:10	Antimicrobial resistance activities		
	<ul> <li>The European Commission's action plan against the rising threats from antimicrobial resistance – a holistic approach</li> </ul>	Karin Krauss, European Commission	
	<ul> <li>Review of recent activities, developments and plans of CVMP</li> </ul>	Karolina Törneke, CVMP	
	<ul> <li>Industry: perspectives for the future</li> </ul>	Declan O'Brien, IFAH-Europe	
	Questions		
15:10	Immunologicals		
	<ul> <li>Review of recent activities, developments and plans</li> </ul>	Nikolaus Križ, EMA	
	Questions		
15:40	Tea and Coffee		
Session II: Scientific Developments <u>Chair</u> : David Mackay, EMA			
16:10	Latest developments in VICH guidelines	Rick Clayton, IFAH-Europe	
16:10	Latest developments in VICH guidelines Questions	Rick Clayton, IFAH-Europe	
16:10 16:40		Rick Clayton, IFAH-Europe	
	Questions	Rick Clayton, IFAH-Europe  Jos Olaerts, EMA	
	Questions  Pharmacovigilance  • Update on developments (including databases, signal		
	Questions  Pharmacovigilance  Update on developments (including databases, signal detection, inspections)	Jos Olaerts, EMA  Marie-Odile Hendrickx,	
	<ul> <li>Questions</li> <li>Pharmacovigilance</li> <li>Update on developments (including databases, signal detection, inspections)</li> <li>Industry perspective</li> </ul>	Jos Olaerts, EMA  Marie-Odile Hendrickx,	
16:40	<ul> <li>Questions</li> <li>Pharmacovigilance</li> <li>Update on developments (including databases, signal detection, inspections)</li> <li>Industry perspective</li> </ul> Questions	Jos Olaerts, EMA  Marie-Odile Hendrickx,	
16:40	Questions  Pharmacovigilance  Update on developments (including databases, signal detection, inspections)  Industry perspective  Questions  New technologies and innovative medicines	Jos Olaerts, EMA  Marie-Odile Hendrickx, Pfizer/IFAH-Europe	
16:40	<ul> <li>Questions</li> <li>Pharmacovigilance</li> <li>Update on developments (including databases, signal detection, inspections)</li> <li>Industry perspective</li> <li>Questions</li> <li>New technologies and innovative medicines</li> <li>Latest thinking on how to manage these</li> </ul>	Jos Olaerts, EMA  Marie-Odile Hendrickx, Pfizer/IFAH-Europe  David Mackay, EMA	
16:40	<ul> <li>Questions</li> <li>Pharmacovigilance</li> <li>Update on developments (including databases, signal detection, inspections)</li> <li>Industry perspective</li> <li>Questions</li> <li>New technologies and innovative medicines</li> <li>Latest thinking on how to manage these</li> <li>Industry perspective</li> </ul>	Jos Olaerts, EMA  Marie-Odile Hendrickx, Pfizer/IFAH-Europe  David Mackay, EMA	
16:40 17:20	<ul> <li>Questions</li> <li>Pharmacovigilance</li> <li>Update on developments (including databases, signal detection, inspections)</li> <li>Industry perspective</li> <li>Questions</li> <li>New technologies and innovative medicines</li> <li>Latest thinking on how to manage these</li> <li>Industry perspective</li> <li>Questions</li> </ul>	Jos Olaerts, EMA  Marie-Odile Hendrickx, Pfizer/IFAH-Europe  David Mackay, EMA	
16:40 17:20	<ul> <li>Questions</li> <li>Pharmacovigilance</li> <li>Update on developments (including databases, signal detection, inspections)</li> <li>Industry perspective</li> <li>Questions</li> <li>New technologies and innovative medicines</li> <li>Latest thinking on how to manage these</li> <li>Industry perspective</li> <li>Questions</li> <li>CVMP Work programme for 2012</li> <li>Including reports on the scientific challenges facing the</li> </ul>	Jos Olaerts, EMA  Marie-Odile Hendrickx, Pfizer/IFAH-Europe  David Mackay, EMA Elanco, IFAH-Europe	
16:40 17:20	<ul> <li>Questions</li> <li>Pharmacovigilance</li> <li>Update on developments (including databases, signal detection, inspections)</li> <li>Industry perspective</li> <li>Questions</li> <li>New technologies and innovative medicines</li> <li>Latest thinking on how to manage these</li> <li>Industry perspective</li> <li>Questions</li> <li>CVMP Work programme for 2012</li> <li>Including reports on the scientific challenges facing the CVMP and the Working Parties of CVMP</li> </ul>	Jos Olaerts, EMA  Marie-Odile Hendrickx, Pfizer/IFAH-Europe  David Mackay, EMA Elanco, IFAH-Europe	





Friday 9 <sup>th</sup> March 2012				
Session III: EMA Procedural Updates and wider international harmonisation Chair: Kornelia Grein, EMA				
09:00	Progress in electronic submission			
	<ul> <li>Project update (Including e-application form project)</li> </ul>	Anne-Christine Lantin, EMA		
	Industry perspective	Corinne-Philippe Reversat, Merial/IFAH-Europe		
	Questions			
09:45	European Medicines Agency Road map to 2015			
	<ul> <li>Progress on implementation</li> </ul>	Melanie Leivers, EMA		
10:00	VICH wider international harmonisation initiative	Brigitte Boenisch, Merial/IFAH- Europe		
	Questions			
10:30	Tea and coffee			
Session IV:	Future Legislation	<u>Chair</u> : Declan O'Brien, IFAH- Europe		
11:00	Update on the review of the legislation	Martinus Nagtzaam, European Commission (TBC)		
11:20	Outcome of Packaging and Labelling workshops			
	<ul> <li>Report from workshops held jointly with CMDv/CVMP/IFAH-Europe/FVE</li> </ul>	Jiří Bureš, CMDv/CVMP		
	Questions			
11:45	SPC harmonisation (CVMP/CMDv Task Force)	Kornelia Grein, EMA		
	Questions			
12:15	IFAH Benchmarking Study	Barbara Freischem, IFAH		
12:35	Close of the meeting	Rick Clayton/Kornelia Grein		